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Association between Impaired Lung Function and 
Cardiovascular Disease Cause, Effect, or Force of Circumstance? 
McAllister DA and Newby DE. 
Large, population-based cohort studies have consistently shown that lung function, and particularly FEV1, 
predicts cardiovascular mortality. For example, in 2005, Sin and colleagues undertook a major systematic 
review comprising a total of 83,880 participants in 12 studies and reported that pulmonary function 
predicted cardiovascular mortality (1). The pooled relative risk for the lowest compared with the highest 
lung function group was 1.99 (95% confidence interval, 1.71-2.29) (1). However, despite the considerable 
interest surrounding cardiovascular comorbidity in chronic obstructive pulmonary disease (COPD) (2), the 
mechanisms underlying this doubling in cardiovascular mortality remain uncertain. 
For many observers, there are three potential hypotheses linking COPD with cardiovascular morbidity and 
mortality. First, reduced lung function may cause cardiovascular disease through increased systemic 
inflammation, promoting atheromatous disease and a prothrombotic state (3). Second, shared avoidable 
risk factors, such as smoking habit and other environmental factors, may simultaneously and independently 
cause endothelial dysfunction in both the pulmonary and systemic vasculature, with resultant disease in 
both organ systems (4). Finally, lung function may, similar to height, reflect a range of adverse fetal and 
early life factors, predisposing individuals to increased cardiovascular risk as well as a range of other adverse 
outcomes (5). 
Determining the causal mechanism underlying this well-established association between pulmonary 
function and cardiovascular disease is the subject of the article published in this issue of the Journal by 
Chandra and colleagues (6). It focuses on the first of these possibilities, hypothesizing that reduced 
pulmonary function causes endothelial dysfunction, and subsequently atheroma formation. In a cross-
sectional design incorporating two cohorts of 231 and 328 participants selected from larger population-
based cohorts (the former selected to have a smoking history of >10 pack-years), the authors found that 
reduced FEV1 was moderately associated with markers of atheromatous disease, as identified on B-mode 
carotid ultrasound and non-ECG gated computed tomography coronary artery calcification (odds ratios per 
25% decrement in FEV1  ranged from 1.28 to 1.76 across different measures). They also demonstrated that 
markers of endothelial dysfunction, measured via ultrasound-assessed flow-mediated dilatation and the 
reactive hyperemia index, were moderately associated with atheroma (odds ratios per 1 SD increment 
ranged from 1.30 to 1.36 across different measures). However, importantly, the association between FEV1 
and atheroma was not attenuated by adjusting for endothelial dysfunction, as might have been expected if 
endothelial dysfunction had been a mediator. 
Previous observational studies examining atheroma burden in relation to lung function and emphysema 
have yielded variable results (7-12). In the Multi-Ethnic Study of Atherosclerosis study, coronary artery 
calcification was not associated with FEV1 after adjusting for age, sex, and demographic features (12). 
However, in the largest study, conducted in the Atherosclerosis Risk in Communities study, FEV1  was 
associated with the ankle brachial index (an indirect measure of atheroma), even among never- smokers (9). 
The current study adds weight to the suggestion that atheroma in the coronary arteries may be associated 
with FEV1. 
In the present analysis, flow-mediated dilatation was performed in fasted patients having withheld caffeine, 
alcohol, and inhalers, thereby reducing variability. Moreover, sonographers were blinded to each 
participant's lung function status, making measurement bias less likely. The study participants were drawn 
from population-based cohort studies, making it unlikely that the observed associations were caused by 
selection bias. These methodological strengths increased the reliability and validity of the findings. However, 
although the combined sample size across the two cohorts was likely sufficient to examine the exposure-
outcome association (between FEV1 and atheroma), surprisingly large sample sizes may be needed to 
estimate mediation effects, particularly where the exposure-outcome association is weak or moderate (13). 
As a consequence, the finding that endothelial dysfunction was not a mediator may be a result of random 
error, especially as only noninvasive markers of endothelial function were employed. Nonetheless, as 
discussed by the authors, one potential explanation of these findings is that FEV1 causes atheroma through 
mechanisms independent of endothelial function, such as via increased arterial stiffness or elastocalcinosis 
(14-18). However, another possibility is that FEV1 and cardiovascular disease are not causally related, but 
are simply confounded because of the presence of shared environmental and lifestyle factors (hypothesis 
2). 
As well as cardiovascular disease, reduced pulmonary function predicts a broad range of adverse health 
outcomes, including cancer from all causes, non-respiratory cancer, rupture of aortic aneurysm, and even 
psychiatric illness (5, 19, 20). Moreover, FEV1 is associated with ischemic heart disease mortality in a 
broadly linear fashion, with no evidence of a plateau beyond normal levels of lung function (5). These 
observations are consistent with the view that FEV1 may be a broad marker of cardiovascular risk (and 
health more generally), rather than a specific cause of cardiovascular disease (hypothesis 3). If this is true, 
we can expect more null findings in studies examining causal links among pulmonary function, endothelial 
dysfunction, and cardiovascular disease, such as in the article by Chandra and colleagues (6). 
Life-course epidemiology may help determine the nature of the relationship between FEV1 and 
cardiovascular disease. Both pulmonary function (2l) and cardiovascular risk (22) are known to have early 
life determinants. However, just as clinical trials of effective cholesterol-lowering therapies unequivocally 
demonstrated that serum cholesterol plays a causal role in coronary heart disease, it is likely that clinical 
trials will be needed to resolve the causal question of how pulmonary function relates to cardiovascular risk 
in COPD. The recent Study to Understand Mortality and Morbidity trial examining the use of pulmonary 
therapies in COPD, for example, has included cardiovascular events as a secondary outcome (23). Findings 
from this and other studies intervening on lung function are needed to identify whether reduced pulmonary 
function causes cardiovascular disease in adult life. The debate continues. 
Conflicts of Interest 
DEN is on the Trial Steering Committee of the SUMMIT trial funded by GlaxoSmithKline. 
  
References 
1.  Sin DD, Wu L, Man SFP. The Relationship between Reduced Lung Function and 
Cardiovascular Mortality: A Population-Based Study and a Systematic Review of the Literature. 
Chest. 2005;127: 1952–1959. doi:10.1378/chest.127.6.1952 
2.  Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) 2016 [Internet]. Available: http://www.goldcopd.org/. 
3.  MacNee W, Maclay J, McAllister D. Cardiovascular Injury and Repair in Chronic 
Obstructive Pulmonary Disease. Proc Am Thorac Soc. 2008;5: 824–833. doi:10.1513/pats.200807-
071TH 
4.  Barr RG, Carr JJ, Hoffman EA, Jiang R, Kawut S, Punjabi N, et al. Subclinical 
Cardiovascular Disease in Chronic Obstructive Pulmonary Disease. The MESA Lung Study. San 
Francisco: American Journal of Respiratory and Critical Care Medicine, April 2007;175; 2007. p. 
A516.  
5.  Hole DJ, Watt GCM, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung 
function and mortality risk in men and women: findings from the Renfrew and Paisley prospective 
population study. Br Med J. 1996;313: 711–715.  
6.  Ebrahim S, Papacosta O, Whincup P, Wannamethee G, Walker M, Nicolaides AN, et al. 
Carotid Plaque, Intima Media Thickness, Cardiovascular Risk Factors, and Prevalent 
Cardiovascular Disease in Men and Women : The British Regional Heart Study. Stroke. 1999;30: 
841–850.  
7.  Engström G, Hedblad B, Valind S, Janzon L. Asymptomatic leg and carotid atherosclerosis 
in smokers is related to degree of ventilatory capacity: Longitudinal and cross-sectional results from 
“Men born in 1914”, Sweden. Atherosclerosis. 2001;155: 237–243. doi:10.1016/S0021-
9150(00)00557-8 
8.  Schroeder EB, Welch VL, Evans GW, Heiss G. Impaired lung function and subclinical 
atherosclerosis: The ARIC Study. Atherosclerosis. 2005;180: 367–373. 
doi:10.1016/j.atherosclerosis.2004.12.012 
9.  Zureik M, Kauffmann F, Touboul P-J, Courbon D, Ducimetiere P. Association Between 
Peak Expiratory Flow and the Development of Carotid Atherosclerotic Plaques. Arch Intern Med. 
2001;161: 1669–1676. doi:10.1001/archinte.161.13.1669 
10.  Alhaj EK, Alhaj NE, Bergmann SR, Hecht H, Matarazzo TJ, Smith S, et al. Coronary artery 
calcification and emphysema. Can J Cardiol. 2008;24: 369–372.  
11.  Barr RG, Ahmed FS, Carr JJ, Hoffman EA, Jiang R, Kawut SM, et al. Subclinical 
atherosclerosis, airflow obstruction and emphysema: the MESA Lung Study. Eur Respir J. 2012;39: 
846–854. doi:10.1183/09031936.00165410 
12.  Fritz MS, MacKinnon DP. Required Sample Size to Detect the Mediated Effect. Psychol 
Sci. 2007;18: 233–239. doi:10.1111/j.1467-9280.2007.01882.x 
13.  Bolton CE, Cockcroft JR, Sabit R, Munnery M, McEniery CM, Wilkinson IB, et al. Lung 
function in mid-life compared with later life is a stronger predictor of arterial stiffness in men: The 
Caerphilly Prospective Study. Int J Epidemiol. 2009;38: 867–876.  
14.  Zureik M, Benetos A, Neukirch C, Courbon D, Bean K, Thomas F, et al. Reduced 
Pulmonary Function Is Associated with Central Arterial Stiffness in Men. Am J Respir Crit Care 
Med. 2001;164: 2181–2185.  
15.  Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, et al. Arterial 
Stiffness and Osteoporosis in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 
2007;175: 1259–1265. doi:10.1164/rccm.200701-067OC 
16.  Duprez DA, Hearst MO, Lutsey PL, Herrington DM, Ouyang P, Barr RG, et al. Associations 
among lung function, arterial elasticity, and circulating endothelial and inflammation markers: the 
multiethnic study of atherosclerosis. Hypertension. 2013;61: 542–548. 
doi:10.1161/HYPERTENSIONAHA.111.00272 
17.  McAllister DA, MacNee W, Duprez D, Hoffman EA, Vogel-Claussen J, Criqui MH, et al. 
Pulmonary function is associated with distal aortic calcium, not proximal aortic distensibility. MESA 
lung study. COPD. 2011;8: 71–78. doi:10.3109/15412555.2011.558543 
18.  Pembroke TPI, Rasul F, Hart CL, Davey Smith G, Stansfeld SA. Psychological distress and 
chronic obstructive pulmonary disease in the Renfrew and Paisley (MIDSPAN) study. J Epidemiol 
Community Health. 2006;60: 789–792. doi:10.1136/jech.2005.042150 
19.  Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound 
surveillance. UK Small Aneurysm Trial Participants. Ann Surg. 1999;230: 289–96; discussion 296–
7.  
20.  Jackson B, Wright RJ, Kubzansky LD, Weiss ST. Examining the influence of early life 
socioeconomic position on pulmonary function across the life span: where do we go from here? 
Thorax. 2004;59: 186–188. doi:10.1136/thx.2003.018929 
21.  Sun C, Burgner DP, Ponsonby A-L, Saffery R, Huang R-C, Vuillermin PJ, et al. Effects of 
early-life environment and epigenetics on cardiovascular disease risk in children: highlighting the 
role of twin studies. Pediatr Res. 2013;73: 523–530. doi:10.1038/pr.2013.6 
22.  Vestbo J, Anderson J, Brook RD, Calverley PMA, Celli BR, Crim C, et al. The Study to 
Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013;41: 
1017–1022. doi:10.1183/09031936.00087312 
 
